Bioresorbable everolimus-eluting vascular scaffold for the treatment of chronic total occlusions: CTO-ABSORB pilot study

EuroIntervention

Volumn 11, Issue 5, 2015, Pages 555-563

  Vaquerizo, Beatriz ^a   Barros, Antonio ^a   Pujadas, Sandra ^a   Bajo, Ester ^a   Estrada, Darlene ^a   Miranda Guardiola, F ^b   Rigla, Juan ^c   Jiménez, Marcelo ^a   Cinca, Juan ^a   Serra, Antonio ^a  

^a HOSPITAL SANT PAU   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTERY REOCCLUSION; ARTICLE; BIORESORBABLE SCAFFOLD; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY CHRONIC TOTAL OCCLUSION; CORONARY ARTERY OCCLUSION; CORONARY ARTERY RECANALIZATION; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GENDER; HUMAN; IN-STENT RESTENOSIS; INTRAVASCULAR ULTRASOUND; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY; PATIENT SAFETY; PILOT STUDY; PROSPECTIVE STUDY; RIGHT CORONARY ARTERY; STENT MALAPPOSITION; AGED; BIODEGRADABLE IMPLANT; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; MIDDLE AGED; PATHOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; RADIOGRAPHY; REGISTER; TISSUE SCAFFOLD;

ANTINEOPLASTIC AGENT; EVEROLIMUS;

ABSORBABLE IMPLANTS; AGED; ANTINEOPLASTIC AGENTS; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; EVEROLIMUS; FEMALE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PILOT PROJECTS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; REGISTRIES; TISSUE SCAFFOLDS; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84976322384     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJY14M12_07     Document Type: Article

References (21)

1. Prasad A, Rihal CS, Lennon RJ, Wiste HJ, Singh M, Holmes DR Jr. Trends in outcomes after percutaneous coronary intervention for chronic total occlusions: a 25-year experience from the Mayo Clinic. J Am Coll Cardiol. 2007;49:1611-8.
2. Suttorp MJ, Laarman GJ, Rahel BM, Kelder JC, Bosschaert MA, Kiemeneij F, Ten Berg JM, Bal ET, Rensing BJ, Eefting FD, Mast EG. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation. 2006;114:921-8.
3. Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA, Granada JF, Marulkar S, Nassif D, Cohen DJ, Kleiman NS; EVENT Registry Investigators. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA. 2007;297:2001-9.
4. Wöhrle J. Stent thrombosis in the era of drug-eluting stents. Herz. 2007;32:411-8.
5. Onuma Y, Serruys PW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation. 2011;123:779-97.
6. Ormiston, JA, Serruys PW, Onuma Y, van Geuns RJ, de Bruyne B, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Rapoza R, Garcia-Garcia HM. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multiimaging modality study. Circ Cardiovasc Interv. 2012;5:620-32.
7. Meincke F, Kuck KH, Bergmann MW. Delivery of bioresorbable vascular scaffold to complex lesions. Catheter Cardiovasc Interv. 2014:84;774-8.
8. Di Mario C, Werner GS, Sianos G, Galassi AR, Bttner J, Dudek D, Chevalier B, Lefevre T, Schofer J, Koolen J, Sievert H, Reimers B, Fajadet J, Colombo A, Gershlick A, Serruys PW, Reifart N. European perspective in the recanalisation of Chronic Total Occlusions (CTO): consensus document from the EuroCTO Club. EuroIntervention. 2007;3:30-43.
9. Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Miquel-Hebert K, Rapoza R, García-García HM. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation. 2010;122:2301-12.
10. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S; ESC Committee for Practice Guidelines (CPG). Third universal definition of mycardial infarction. Eur Heart J. 2012;33: 2551-67.
11. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G. A simple risk score for prediction of contrasted-induced nephropathy after percutaneous coronary intervention. J Am Coll Cardiol. 2004;44:1393-9.
12. Muramatsu T, Onuma Y, García-García HM, Farooq V, Bourantas CV, Morel MA, Li X, Veldhof S, Bartorelli A, Whitbourn R, Abizaid A, Serruys PW; ABSORB-EXTEND Investigators. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials. JACC Cardiovasc Interv. 2013;6:247-57.
13. Garrone P, Biondi-Zoccai G, Salvetti I, Sina N, Sheiban I, Stella PR, Agostoni P. Quantitative coronary angiography in the current era: principles and applications. J Interv Cardiol. 2009;22: 527-36.
14. Morino Y, Abe M, Morimoto T, Kimura T, Hayashi Y, Muramatsu T, Ochiai M, Noguchi Y, Kato K, Shibata Y, Hiasa Y, Doi O, Yamashita T, Hinohara T, Tanaka H, Mitsudo K; J-CTO Registry Investigators. Predicting successful guidewire crossing through chronic total occlusion of native coronary lesions within 30 minutes: the J-CTO (Multicenter CTO Registry in Japan) score as a difficulty grading and time assessment tool. JACC Cardiovasc Interv. 2011;4:213-21.
15. Galassi AR, Tomasello SD, Reifart N. In-hospital outcomes of percutaneous coronary intervention in patients with chronic total occlusion: insights from the ERCTO (European Registry of Chronic Total Occlusion) registry. EuroIntervention. 2011;7:472-9.
16. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;115:2435-41.
17. Gogas BD, Serruys PW, Diletti R, Farooq V, Brugaletta S, Radu MD, Heo JH, Onuma Y, van Geuns RJ, Regar E, De Bruyne B, Chevalier B, Thuesen L, Smits PC, Dudek D, Koolen J, Windecker S, Whitbourn R, Miquel-Hebert K, Dorange C, Rapoza R, Garcia-Garcia HM, McClean D, Ormiston JA. Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial. JACC Cardiovasc Interv. 2012;5:656-65.
18. Diletti R, Serruys PW, Farooq V, Sudhir K, Dorange C, Miquel-Hebert K, Veldhof S, Rapoza R, Onuma Y, Garcia-Garcia HM, Chevalier B. ABSORB II randomized controlled trial. A clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Am Heart J. 2012;164:654-63.
19. Sakakura K, Nakano M, Otsuka F, Yahagi K, Kutys R, Ladich E, Finn AV, Kolodgie FD, Virmani R. Comparison of pathology of chronic total occlusion with and without coronary artery bypass graft. Eur Heart J. 2014;35:1683-93.
20. Onuma Y, Serruys PW, Ormiston JA, Regar E, Webster M, Thuesen L, Dudek D, Veldhof S, Rapoza R. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention. 2010;6:447-53.
21. Bruining N, Tanimoto S, Otsuka M, Weustink A, Ligthart J, de Winter S, van Mieghem C, Nieman K, de Feyter PJ, van Domburg RT, Serruys PW. Quantitative multi-modality imaging analysis of a bioabsorbable poly-l-lactic acid stent design in the acute phase: a comparison between 2- and 3D-QCA, QCU and QMSCT-CA. EuroIntervention. 2008;4:285-91.